\-\ Texto\\:\\ \ \(0\)\
\-\ thin\\ appearing\ \(0\)\
\-\ aaox3\ \(0\)\
\-\ mmm\ \(3\)\
\-\ rrr\ \(3\)\
\-\ cta\\ b\\/l\ \(0\)\
\-\ abd\\ soft\\/nt\\/nd\\/nabs\ \(0\)\
\-\ ext\\ w\\/o\\ edema\ \(0\)\
\-\ referred\\ to\\ oncology\\ service\\ for\\ chemotherapy\\.\\ poor\\ prognosis\\.\ \(0\)\
\-\ \\â\\€\\¢\\ abd\\ ct\\:\\ too\\ numerous\\ to\\ count\\ low\\ attenuation\\ lesions\\ in\\ the\\ liver\\.\\ variable\\ in\\ size\\,\\ from\\ sub\\-centimeter\\ to\\ \\>4cm\\ coalescent\\ lesions\\.\\ \ \(0\)\
\-\ there\\ is\\ a\\ single\\ hypodense\\ lesion\\ in\\ the\\ spleen\\.\ \(0\)\
\-\ metastasis\\,\\ melanoma\ \(0\)\
\-\ \\â\\€\\¢\\ metastases\ \(0\)\
\-\ \\â\\€\\¢\\ abscesses\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ hepatocellular\\ carcinoma\ \(0\)\
\-\ 55\\ y\\.o\\.\\ man\\ with\\ weight\\ loss\\ and\\ fatigue\\ for\\ 1\\ month\ \(1\)\
\-\ metastatic\\ cancer\\ is\\ the\\ most\\ common\\ malignant\\ tumor\\ of\\ the\\ liver\\.\\ the\\ ratio\\ of\\ metastatic\\ disease\\ to\\ primary\\ liver\\ tumors\\ is\\ 18\\:1\\.\\ \\ imaging\\ appearance\\ varies\\ based\\ on\\ the\\ primary\\ tumor\\ origin\\.\\ lung\\,\\ gi\\,\\ lymphoma\\,\\ and\\ most\\ breast\\ cancers\\ are\\ hypovascular\\ lesions\\.\\ on\\ ct\\ these\\ lesions\\ will\\ generally\\ appear\\ as\\ low\\ attenuation\\ with\\ peripheral\\ enhancement\\.\\ \\ these\\ findings\\ indicate\\ a\\ necrotic\\/hypovascular\\ center\\ with\\ a\\ well\\ vascularized\\ viable\\ tumor\\ in\\ the\\ periphery\\.\\ endocrine\\,\\ renal\\,\\ thyroid\\,\\ sarcomas\\ and\\ melanomas\\ are\\ generally\\ hypervascular\\ lesions\\.\\ on\\ contrast\\ enhanced\\ ct\\ they\\ appear\\ hyperdense\\ in\\ late\\ arterial\\ phase\\ images\\.\\ some\\ lesions\\ can\\ have\\ variable\\ enhancement\\ secondary\\ to\\ internal\\ necrosis\\.\\ on\\ non\\-contrast\\ enhanced\\ ct\\ or\\ portal\\ venous\\ images\\ these\\ lesions\\ appear\\ iso\\-\\ or\\ hypodense\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ blake\\ sp\\ et\\ al\\:\\ liver\\ metastases\\ from\\ melanoma\\:\\ detection\\ with\\ multiphasic\\ contrast\\-enhanced\\ ct\\.\\ radiology\\.\\ 213\\(1\\)\\:92\\-6\\,\\ 1999\ \(0\)\
\-\ \\	\ \(2191\)\
\-\ paulson\\ ek\\ et\\ al\\:\\ carcinoid\\ metastases\\ to\\ the\\ liver\\:\\ role\\ of\\ triple\\-phase\\ helical\\ ct\\.\\ radiology\\.\\ 206\\(1\\)\\:143\\-50\\,\\ 1998\ \(0\)\
\-\ https\\:\\/\\/my\\.statdx\\.com\\/statdxmain\\.jsp\\#5\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lesions\\:\\ 0\\.27098730351532263\ \(0\)\
\-\ liver\\:\\ 0\\.23250152292440415\ \(0\)\
\-\ hypovascular\\:\\ 0\\.18283334024649428\ \(0\)\
\-\ metastases\\:\\ 0\\.16348384313058828\ \(0\)\
\-\ appear\\:\\ 0\\.15926516375053915\ \(0\)\
\-\ ct\\:\\ 0\\.15397433837296548\ \(0\)\
\-\ enhanced\\:\\ 0\\.1539738562297989\ \(0\)\
\-\ variable\\:\\ 0\\.13090544336698973\ \(0\)\
\-\ hypodense\\:\\ 0\\.13090544336698973\ \(0\)\
\-\ melanoma\\:\\ 0\\.12589586472207395\ \(0\)\
\-\ abd\\:\\ 0\\.12537065634456043\ \(0\)\
\-\ phase\\:\\ 0\\.11535920531275816\ \(0\)\
\-\ generally\\:\\ 0\\.11419803261689934\ \(0\)\
\-\ these\\:\\ 0\\.11419377493046416\ \(0\)\
\-\ radiology\\:\\ 0\\.10797258149804993\ \(0\)\
\-\ multiphasic\\:\\ 0\\.10779809771408205\ \(0\)\
\-\ paulson\\:\\ 0\\.10779809771408205\ \(0\)\
\-\ the\\:\\ 0\\.10760074260736455\ \(0\)\
\-\ al\\:\\ 0\\.1071175330449828\ \(0\)\
\-\ tumor\\:\\ 0\\.10577295287604452\ \(0\)\
\-\ et\\:\\ 0\\.10560726865342855\ \(0\)\
\-\ attenuation\\:\\ 0\\.10315102712949764\ \(0\)\
\-\ melanomas\\:\\ 0\\.10300683728962338\ \(0\)\
\-\ to\\:\\ 0\\.10110935866942738\ \(0\)\
\-\ ek\\:\\ 0\\.0996073839186646\ \(0\)\
\-\ contrast\\:\\ 0\\.09825471797585855\ \(0\)\
\-\ coalescent\\:\\ 0\\.09481612349420593\ \(0\)\
\-\ blake\\:\\ 0\\.09481612349420593\ \(0\)\
\-\ 206\\:\\ 0\\.09481612349420593\ \(0\)\
\-\ vascularized\\:\\ 0\\.09299457082076919\ \(0\)\
\-\ 213\\:\\ 0\\.09299457082076919\ \(0\)\
\-\ sp\\:\\ 0\\.09141667012324714\ \(0\)\
\-\ sarcomas\\:\\ 0\\.08480385702535172\ \(0\)\
\-\ helical\\:\\ 0\\.08480385702535172\ \(0\)\
\-\ in\\:\\ 0\\.08384308217955096\ \(0\)\
\-\ primary\\:\\ 0\\.08289578188394695\ \(0\)\
\-\ viable\\:\\ 0\\.08183414927432978\ \(0\)\
\-\ on\\:\\ 0\\.08143200471445106\ \(0\)\
\-\ lymphoma\\:\\ 0\\.080289809235127\ \(0\)\
\-\ enhancement\\:\\ 0\\.0775963253547378\ \(0\)\
\-\ varies\\:\\ 0\\.0774888550655931\ \(0\)\
\-\ low\\:\\ 0\\.07735673774102558\ \(0\)\
\-\ https\\:\\ 0\\.07431885943199663\ \(0\)\
\-\ metastatic\\:\\ 0\\.07393848137043749\ \(0\)\
\-\ endocrine\\:\\ 0\\.07331966996105854\ \(0\)\
\-\ cancers\\:\\ 0\\.07239842164448582\ \(0\)\
\-\ 1998\\:\\ 0\\.07239842164448582\ \(0\)\
\-\ oncology\\:\\ 0\\.0721066363956077\ \(0\)\
\-\ hypervascular\\:\\ 0\\.07127216963558872\ \(0\)\
\-\ 4cm\\:\\ 0\\.07100661459098594\ \(0\)\
\-\ carcinoid\\:\\ 0\\.07100661459098594\ \(0\)\
\-\ role\\:\\ 0\\.07074689639618027\ \(0\)\
\-\ detection\\:\\ 0\\.07024398210795353\ \(0\)\
\-\ most\\:\\ 0\\.07016104725355563\ \(0\)\
\-\ service\\:\\ 0\\.06976160075655943\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.06929814127017564\ \(0\)\
\-\ indicate\\:\\ 0\\.06863534874766233\ \(0\)\
\-\ abscesses\\:\\ 0\\.06842242943451679\ \(0\)\
\-\ periphery\\:\\ 0\\.06800776575941479\ \(0\)\
\-\ too\\:\\ 0\\.06780576593157484\ \(0\)\
\-\ 1999\\:\\ 0\\.06780576593157484\ \(0\)\
\-\ ratio\\:\\ 0\\.06760716122002715\ \(0\)\
\-\ spleen\\:\\ 0\\.06561799293944372\ \(0\)\
\-\ fatigue\\:\\ 0\\.06528973010386714\ \(0\)\
\-\ portal\\:\\ 0\\.06450688084571697\ \(0\)\
\-\ late\\:\\ 0\\.06363116901005811\ \(0\)\
\-\ images\\:\\ 0\\.06236023651121576\ \(0\)\
\-\ hyperdense\\:\\ 0\\.06205326831253607\ \(0\)\
\-\ center\\:\\ 0\\.06099434812213173\ \(0\)\
\-\ prognosis\\:\\ 0\\.059318382943347764\ \(0\)\
\-\ origin\\:\\ 0\\.058024640371109805\ \(0\)\
\-\ 55\\:\\ 0\\.05793743184116171\ \(0\)\
\-\ numerous\\:\\ 0\\.05693824237022361\ \(0\)\
\-\ poor\\:\\ 0\\.05685866831750661\ \(0\)\
\-\ gi\\:\\ 0\\.056623111636951336\ \(0\)\
\-\ count\\:\\ 0\\.0556533745277862\ \(0\)\
\-\ arterial\\:\\ 0\\.05551100289984915\ \(0\)\
\-\ is\\:\\ 0\\.05537940474584209\ \(0\)\
\-\ appearing\\:\\ 0\\.05386255451711859\ \(0\)\
\-\ references\\:\\ 0\\.053740100549027066\ \(0\)\
\-\ from\\:\\ 0\\.05354222158800163\ \(0\)\
\-\ thyroid\\:\\ 0\\.052973661751845466\ \(0\)\
\-\ with\\:\\ 0\\.05279635211513488\ \(0\)\
\-\ single\\:\\ 0\\.051831851212492674\ \(0\)\
\-\ necrosis\\:\\ 0\\.051524906625840826\ \(0\)\
\-\ are\\:\\ 0\\.05115560619163554\ \(0\)\
\-\ referred\\:\\ 0\\.049877773387314146\ \(0\)\
\-\ tumors\\:\\ 0\\.049574208380886664\ \(0\)\
\-\ metastasis\\:\\ 0\\.049404180955755474\ \(0\)\
\-\ breast\\:\\ 0\\.04894884012456839\ \(0\)\
\-\ based\\:\\ 0\\.048827642116745236\ \(0\)\
\-\ peripheral\\:\\ 0\\.048201445170628666\ \(0\)\
\-\ they\\:\\ 0\\.048163388125901097\ \(0\)\
\-\ venous\\:\\ 0\\.04812545325488204\ \(0\)\
\-\ malignant\\:\\ 0\\.04804994691379693\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.047863265271756376\ \(0\)\
\-\ weight\\:\\ 0\\.0470060894433085\ \(0\)\
\-\ or\\:\\ 0\\.04689922914918741\ \(0\)\
\-\ size\\:\\ 0\\.04564110805893199\ \(0\)\
\-\ internal\\:\\ 0\\.04542818874578645\ \(0\)\
\-\ cancer\\:\\ 0\\.044897674121428914\ \(0\)\
\-\ will\\:\\ 0\\.04338479976933136\ \(0\)\
\-\ some\\:\\ 0\\.04241168211310439\ \(0\)\
\-\ renal\\:\\ 0\\.04197609964337042\ \(0\)\
\-\ and\\:\\ 0\\.04178635050721586\ \(0\)\
\-\ loss\\:\\ 0\\.041066673941264634\ \(0\)\
\-\ month\\:\\ 0\\.04100431652914883\ \(0\)\
\-\ lung\\:\\ 0\\.04100431652914883\ \(0\)\
\-\ for\\:\\ 0\\.04086094856040747\ \(0\)\
\-\ appearance\\:\\ 0\\.04063692832132777\ \(0\)\
\-\ carcinoma\\:\\ 0\\.040319682363459515\ \(0\)\
\-\ edema\\:\\ 0\\.04020287710754697\ \(0\)\
\-\ secondary\\:\\ 0\\.039953691672306633\ \(0\)\
\-\ of\\:\\ 0\\.03957361885851307\ \(0\)\
\-\ common\\:\\ 0\\.038227358709703445\ \(0\)\
\-\ man\\:\\ 0\\.035685980302213004\ \(0\)\
\-\ imaging\\:\\ 0\\.035424538173904535\ \(0\)\
\-\ can\\:\\ 0\\.035372936772368226\ \(0\)\
\-\ have\\:\\ 0\\.033673378353658606\ \(0\)\
\-\ findings\\:\\ 0\\.033267944074110926\ \(0\)\
\-\ well\\:\\ 0\\.03263868971254802\ \(0\)\
\-\ lesion\\:\\ 0\\.03231630444094042\ \(0\)\
\-\ disease\\:\\ 0\\.028294966873783592\ \(0\)\
\-\ as\\:\\ 0\\.027079691295289032\ \(0\)\
\-\ there\\:\\ 0\\.026820944087356764\ \(0\)\
